Ultragenyx Pharmaceutical Inc. beat EPS estimates 0% of the time across 1 reported quarters (0 beats, 1 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-1.24 | — | — | Miss |
| Q12026 FY2026 | $-1.55 | $-1.84 | -18.7% | Miss |
Back to RARE overview · RARE holders · RARE KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.